IN8BIO INC
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(30,437) | $(30,007) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 976 | 962 |
| Non-cash stock-based compensation | 5,000 | 4,370 |
| Amortization of finance lease right-of-use assets | 859 | 871 |
| Amortization of operating lease right-of-use assets | 820 | 668 |
| Loss on disposal of construction in progress | 45 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,889 | 689 |
| Other non-current assets | (20) | — |
| Accounts payable | (535) | (981) |
| Accrued expenses and other current liabilities | (1,908) | 796 |
| Short-term operating lease liabilities | 134 | 112 |
| Long-term operating lease liabilities | (972) | (820) |
| Net cash used in operating activities | (24,149) | (23,340) |
| Investing activities | ||
| Purchases of property and equipment | (104) | (405) |
| Construction in progress | (83) | (195) |
| Net cash used in investing activities | (187) | (600) |
| Financing activities | ||
| Payment of issuance costs from December 2023 issuance of common stock | (89) | — |
| Proceeds from the issuance of common stock, net of issuance costs | 3,816 | 14,380 |
| Proceeds from the exercise of Series A warrants, net of issuance costs | 25 | — |
| Proceeds from private placement common stock, net of issuance costs | 6,127 | 10,184 |
| Proceeds from private placement warrants, net of issuance costs | 5,099 | 3,278 |
| Principal payments on finance leases | (794) | (798) |
| Net cash provided by financing activities | 14,184 | 27,044 |
| Net (decrease) increase in cash and restricted cash | (10,152) | 3,104 |
| Cash and restricted cash at beginning of year | 21,538 | 18,434 |
| Cash and restricted cash at end of year | $11,386 | $21,538 |
| Supplemental disclosure of non-cash operating, financing and investing information: | ||
| Initial measurement of operating lease right-of-use assets and liabilities | $714 | $— |
| Initial measurement of finance lease right-of-use assets and liabilities | $564 | $536 |
| Lease modification of operating lease right-of-use assets and liabilities | $492 | $— |
| Lease modification of finance lease right-of-use assets and liabilities | $— | $7 |
| Transfer of construction in progress to property and equipment | $221 | $29 |
Statements of Cash Flows Continued
(In thousands)
The following table provides a reconciliation of cash and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Cash, end of year | $11,120 | $21,282 |
| Restricted cash, end of year | 266 | 256 |
| Cash and restricted cash, end of year | $11,386 | $21,538 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.